Ontology highlight
ABSTRACT:
SUBMITTER: Suzuki K
PROVIDER: S-EPMC5928154 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Suzuki Kenshi K Dimopoulos Meletios A MA Takezako Naoki N Okamoto Shinichiro S Shinagawa Atsushi A Matsumoto Morio M Kosugi Hiroshi H Yoon Sung-Soo SS Huang Shang-Yi SY Qin Xiang X Qi Ming M Iida Shinsuke S
Blood cancer journal 20180501 4
In the phase 3 POLLUX study, daratumumab plus lenalidomide and dexamethasone (DRd) significantly reduced the risk of progression/death and induced deeper responses vs. lenalidomide and dexamethasone alone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM). We report a subgroup analysis of East Asian (Japanese, Korean, and Taiwanese) patients from POLLUX based on a longer follow-up of 24.7 months. Median progression-free survival was not reached (NR) for DRd vs. 13.8 months for Rd ...[more]